Efficacy outcomes of nivolumab + cabozantinib versus pembrolizumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC).

Bradley Alexander McGregor,Daniel M. Geynisman,Mauricio Burotto,Camillo Porta,Cristina Rodríguez,María T. Bourlon,Pedro C. Barata,Shuchi Gulati,Brian Stwalley,Viviana Del Tejo,Ella X. Du,Aozhou Wu,Andi Chin,Keith A. Betts,S. Huo,Toni K. Choueiri

Efficacy outcomes of nivolumab + cabozantinib versus pembrolizumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC).

2021

Bradley Alexander McGregor
Daniel M. Geynisman
Mauricio Burotto
Camillo Porta
Cristina Rodríguez
María T. Bourlon
Pedro C. Barata
Shuchi Gulati
Brian Stwalley
Viviana Del Tejo
Ella X. Du
Aozhou Wu
Andi Chin
Keith A. Betts
S. Huo
Toni K. Choueiri

4578Background: Nivolumab in combination with cabozantinib (N+C) has demonstrated significantly improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS), c...

Keywords:

Medicine
Nivolumab
Internal medicine
objective response
Pembrolizumab
in patient
Cabozantinib
Renal cell carcinoma
Axitinib
indirect comparison
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations